Drug Profile
Research programme: microbiome therapeutics - NuBiyota/Takeda
Alternative Names: Microbial Ecosystem Therapeutic productsLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator NuBiyota
- Developer NuBiyota; Takeda
- Class Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastrointestinal disorders
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Gastrointestinal-disorders in USA (PO)
- 10 Apr 2017 Takeda and NuBiyota enter into a collaboration for the development of microbiome therapeutics for Gastrointestinal disorders
- 10 Apr 2017 Early research in Gastrointestinal disorders in USA (PO)